Revolution Medicines Insider Kelsey Sells Shares, Exercises Options at $4.73
Rhea-AI Filing Summary
Insider transactions by Stephen Michael Kelsey at Revolution Medicines (RVMD) show option exercises and systematic sales under a 10b5-1 plan adopted February 28, 2025. On September 11 and September 15, 2025, the reporting person acquired stock options exercisable at $4.73 (100,000 and 25,000 options) and sold portions of common stock in multiple trades at weighted average sale prices reported as $43.5771, $44.4847, $45.9175 and $46.9302. The filing reports beneficial ownership of 289,414 shares of common stock (direct) following the transactions and includes restricted stock units of 94,426 within holdings. The transactions were executed pursuant to the 10b5-1 plan and were signed by an attorney-in-fact on behalf of the reporting person.
Positive
- Transactions were executed under a 10b5-1 plan, indicating pre-established trading instructions (adopted February 28, 2025).
- Form 4 discloses weighted-average sale prices and price ranges and includes an attorney-in-fact signature, supporting disclosure completeness.
Negative
- Significant share sales occurred (total reported disposals: 44,059; 55,941; 23,682; 1,318 across listed trades), which reduce the reporting person’s direct holdings.
- Filing does not state the total number of shares sold aggregated across all price ranges beyond the line-item amounts and weighted averages (additional detail available only upon request as noted).
Insights
TL;DR: Insider sold shares under a 10b5-1 plan while retaining substantial direct holdings and option positions.
The Form 4 documents option-related acquisitions at an exercise price of $4.73 and multiple block sales at weighted average prices between $43.58 and $46.93. The sales were executed under a pre-established 10b5-1 plan, which can indicate rule-compliant, pre-planned monetization rather than ad hoc sales. Reported direct beneficial ownership after these transactions is 289,414 common shares and the filing discloses 94,426 restricted stock units included within ownership. For investors, the filing conveys liquidity activity by a senior executive (President, Research and Development) but does not by itself provide evidence of company performance or near-term material events.
TL;DR: Transactions follow governance best practice by using a 10b5-1 plan; filings are properly disclosed with execution-price ranges noted.
The filing states the 10b5-1 trading plan adoption date and provides weighted-average sale prices plus execution-price ranges for the multiple trades, and includes an attorney-in-fact signature. This level of disclosure supports transparency and compliance with Section 16 reporting obligations. The filing does not reveal any changes to officer status or other governance actions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 25,000 | $0.00 | -- |
| Exercise | Common Stock | 25,000 | $4.73 | $118K |
| Sale | Common Stock | 23,682 | $45.9175 | $1.09M |
| Sale | Common Stock | 1,318 | $46.9302 | $62K |
| Exercise | Stock Option (Right to Buy) | 100,000 | $0.00 | -- |
| Exercise | Common Stock | 100,000 | $4.73 | $473K |
| Sale | Common Stock | 44,059 | $43.5771 | $1.92M |
| Sale | Common Stock | 55,941 | $44.4847 | $2.49M |
Footnotes (1)
- Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 28, 2025. Includes 94,426 restricted stock units. The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
